Design Therapeutics Inc
Suletud
10.6 -0.84
Ülevaade
Aktsiahinna muutus
24h
Min
10.51
Max
10.74
Sissetulek | -1.6M -18M |
|---|---|
Aktsiakasum | -0.29 |
Töötajad | 54 |
EBITDA | -1.5M -20M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +84.04% upside |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | -148M 652M |
|---|---|
Eelmine avamishind | 11.44 |
Eelmine sulgemishind | 10.6 |
Design Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Design Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
84.04% tõus
12 kuu keskmine prognoos
Keskmine 19.6 USD 84.04%
Kõrge 22 USD
Madal 15 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Design Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Design Therapeutics Inc
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
